Kazia Therapeutics Limited
13
4
5
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
7.7%
1 terminated/withdrawn out of 13 trials
85.7%
-0.8% vs industry average
0%
0 trials in Phase 3/4
33%
2 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Role: collaborator
Genetic Testing in Guiding Treatment for Patients With Brain Metastases
Role: collaborator
5G-PEARL: Paxalisib in Malignant Brain Tumours
Role: collaborator
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer
Role: collaborator
GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases
Role: collaborator
Paxalisib With a High Fat, Low Carb Diet and Metformin for Glioblastoma
Role: collaborator
Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients With Advanced Solid Tumours
Role: lead
Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL
Role: collaborator
Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma
Role: lead
Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer.
Role: lead
Mass Balance Recovery, Metabolite Profile, and Metabolite Identification of [14C]-Paxalisib in Healthy Male Subjects
Role: lead
Study of GDC-0084 in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Diffuse Midline Gliomas
Role: collaborator
Phenoxodiol in Treating Patients With Refractory Solid Tumors
Role: lead
All 13 trials loaded